Serological responses to the MVA-based JYNNEOS monkeypox vaccine in a cohort of participants from the Democratic Republic of Congo

The current worldwide monkepox outbreak has reaffirmed the continued threat monkeypox virus (MPXV) poses to public health. JYNNEOS, a Modified Vaccinia Ankara (MVA)-based live, non-replicating vaccine, was recently approved for monkeypox prevention for adults at high risk of MPXV infection in the Un...

Descripción completa

Detalles Bibliográficos
Autores principales: Priyamvada, Lalita, Carson, William C., Ortega, Eddy, Navarra, Terese, Tran, Stephanie, Smith, Todd G., Pukuta, Elisabeth, Muyamuna, Elisabeth, Kabamba, Joelle, Nguete, Beatrice U., Likafi, Toutou, Kokola, Gaston, Lushima, Robert Shongo, Tamfum, Jean-Jacques Muyembe, Okitolonda, Emile W., Kaba, Didine K., Monroe, Benjamin P., McCollum, Andrea M., Petersen, Brett W., Satheshkumar, Panayampalli S., Townsend, Michael B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9635871/
https://www.ncbi.nlm.nih.gov/pubmed/36344361
http://dx.doi.org/10.1016/j.vaccine.2022.10.078

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9635871/
https://www.ncbi.nlm.nih.gov/pubmed/36344361
http://dx.doi.org/10.1016/j.vaccine.2022.10.078

Ejemplares similares